title: [Factors influencing the progression-free survival time of prostate cancer patients after endocrine therapy].
abstract: OBJECTIVE
  The progression of prostate cancer (PCa) after endocrine therapy varies widely in different PCa patients. This study aims to analyze the factors that influence the progression-free survival time of PCa patients after endocrine therapy in an attempt to improve the prognosis of the disease.
  
  
  METHODS
  We reviewed the clinicopathological data of 116 cases of prostate cancer treated by endocrine therapy, analyzed the clinicopathological factors that influence the progression-free survival time of PCa patients using univariate (log-rank test) and multivariate Cox proportional hazard models, and investigated the correlation among these factors by Spearman rank correlation analysis.
  
  
  RESULTS
  In the stepwise Cox proportional hazard model, the independent prognostic factors for PCa progression after endocrine therapy were found to be Gleason score (P < 0.01) and clinical stages (P < 0.01). The hazard of PCa progression after endocrine therapy increased 2.126 times that of the baseline for each unit of increase in Gleason score, and 6.625 times for each unit of increase in the clinical stage. The pretreatment PSA level was correlated with both clinical stages (P < 0.01) and Gleason score (P < 0.01).
  
  
  CONCLUSIONS
  Clinical stages and Gleason score were important factors that influenced the progression-free survival time after endocrine therapy in this cohort of PCa patients.
authors: Department of Urology, Drum Tower School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu 210008, China. guanyangbo123@163.com
authors: Yang-bo
authors: YB
authors: Guan
authors: Yi-fen
authors: YF
authors: Zhang
authors: Hang
authors: H
authors: Wen
authors: Si-qiao
authors: SQ
authors: Zhou
authors: Yu-tian
authors: YT
authors: Dai
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*